

Toxicity Management

Elizabeth M. Gaughan, MD

Associate Professor of Medicine

#LearnACI













- No relevant financial relationships to disclose
- I will be discussing non-FDA approved indications during my presentation.








- Incidence, onset and severity grading
- Immune checkpoint inhibitors
 - Common adverse events
 - Rare but serious adverse events
 - Impact of irAEs on cancer outcomes
- Cellular therapies
 - Adverse events and management
- Immunotherapy in special patient populations
- Case studies






Immune-related adverse events (irAEs)

- Immune checkpoint inhibitor (ICI) toxicities often have delayed onset and prolonged duration relative to cytotoxic chemotherapy
- Toxicities result from activation of the immune response, and can mimic a number of autoimmune medical conditions





Onset of irAEs



• Can be days to months after therapy initiation

- May occur even after treatment is discontinued
- Onset may be earlier with combination treatments
- Important to identify patients who are currently
 OR previously on ICI treatment!



Pallin, Acad Emerg Med 2018 Puzanov and Diab, JITC 2017



Common terminology criteria for adverse events

CTCAE Grade	Clinical description	
1	Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated	
2	Moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate instrumental ADL	
3	Severe or medically significant but not immediately life- threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL	
4	Life-threatening consequences; urgent intervention indicated	
5	Death related to adverse event	





- Incidence, onset and severity grading
- Immune checkpoint inhibitors
 - Common adverse events
 - Rare but serious adverse events
 - Impact of irAEs on cancer outcomes
- Cellular therapies
 - Adverse events and management
- Immunotherapy in special patient populations
- Case studies





Toxicity with immune checkpoint inhibitors

100 Percent of patients in clinical trials 90 80 70 60 50 40 30 20 10 0 PD-(L)1 pathway CTLA-4 pathway Immunotherapy Immunotherapy + Chemotherapy combination chemotherapy


Adverse events in clinical trials

■ All-grade ■ Grade 3+






Toxicity with immune checkpoint inhibitors



#LearnACI




Common irAEs with ICIs



Puzanov and Diab, JITC 2017. NCCN Guidelines. Management of immunotherapyrelated toxicities. Version 2.2019.







Puzanov and Diab, JITC 2017. NCCN Guidelines. Management of immunotherapyrelated toxicities. Version 2.2019.

© 2020–2021 Society for Immunotherapy of Cancer



#LearnACI



Diarrhea/Colitis

- Diagnostic evaluation
 - Rule out alternative diagnosis: C.difficile, other GI infections
 - Diarrhea while on ICIs should prompt suspicion of immune-mediated colitis
 - Consider testing with colonoscopy
- Management
 - Low threshold for starting corticosteroids given risk for bowel perforation; typical dose is prednisone 1-2 mg/kg/day (or equivalent)
 - No benefit for corticosteroid pre-treatment (budesonide)
 - Colitis that is slow to improve/refractory to steroids: treat with anti-TNF
 - Infliximab 5mg/kg q14 days (1-3 doses typically required)



Severe inflammation with large deep ulcerated mucosa



Moderate to severe inflammation with diffuse/patchy erythema, superficial ulcers, exudate, LOV



Mild inflammation with mild patchy erythema, aphtha, edema or normal mucosa



#LearnACI





- Hepatitis is often asymptomatic, but can lead to treatment discontinuation
- Elevations in AST and/or ALT
- Typically 6-14 weeks after treatment

Grade 1	Grade 2	Grade 3	Grade 4
 Liver function tests weekly 	 Liver function tests weekly Corticosteroids 0.5 mg/kg/day 	 Liver function tests every 1-2 days Withhold ICIs Corticosteroids 1-2 mg/kg/day 	 Liver function tests every 1-2 days Discontinue ICIs Corticosteroids 1-2 mg/kg/day
	 Diagnostic testing includes iron studies, autoimmune hepatitis panel and viral hepatitis panel Taper steroids over 4-6 weeks once LFTs revert to grade ≤ 1 If LFTs do not improve or recur after taper, may administer azathioprine or mycophenolate mofetil Infliximab should not be used, given risk for hepatotoxicity 		






Pneumonitis

- Diagnostic evaluation
 - Symptoms: persistent dry cough, dyspnea on exertion
 - Rule out alternative diagnosis: infection, malignancy
 - Computed tomography
- Management
 - Can escalate quickly, so prompt symptom reporting is important
 - Withhold drug for low-grade
 - Corticosteroids with close follow-up
 - Additional immunosuppression may be needed


Naidoo et al, J Clin Oncol 2016 Suresh, Naidoo et al, J Thoracic Oncol 2018 © 2020–2021 Society for Immunotherapy of Cancer







Discerning pneumonitis from other diagnoses



^a Rashes (Gottron's papules, Heliotrope rash), evidence of synovitis, family history of RA/SLE, history of dry eyes/mouth, Raynaud's phenomenon

^b Steelworkers, farmers, exposures to heavy metals, organic fumes, dusts, birds, etc. ^c such as poorly-formed granulomas, lymphocytic aggregates


^d NSIP vs UIP-pattern, evidence of air-trapping, lobar dominance. ^f may present as complex obstruction (TLCpp – FVCpp > 15).







Thyroid dysfunction

- Hyperthyroid Phase
 - Leaky thyroid, variable symptoms
 - 2-6 weeks duration
- Hypothyroidism Phase
 - Recovery of depleted gland
 - Symptoms: fatigue, hair and skin changes, fluid retention, constipation
 - Transient or permanent
- Management
 - Hormone replacement
 - Endocrinology consultation
 - ICI does not need to be held if this is the only irAE













Hypophysitis

- Diagnostic workup
 - Symptoms:
 - Due to increased intracranial pressure: headache, nausea, blurry vision
 - Due to hormonal deficit: fatigue, weakness, hypotension
 - Lab tests: ACTH, TSH, FSH, LH, GH, prolactin
 - Differentiate from primary adrenal insufficiency and hypothyroidism by lab results
 - Enhancement/swelling of pituitary on imaging



06/30/04 - Baseline (4.5 mm)



12/03/04 - Headache/fatigue (10.8 mm)

- Management
 - Hormone supplementation

Ryder et al, Endocr Relat Cancer 2014 © 2020–2021 Society for Immunotherapy of Cancer







Pre-treatment screening recommended by SITC

- Patient History
 - Autoimmune, infectious, endocrine, organ-specific diseases
 - Baseline bowel habits
- Dermatologic
 - Full skin and mucosal exam
- Pulmonary
 - Baseline O₂ saturation
- Cardiovascular
 - ECG
 - Troponin I or T

Pazanov & Diab, JITC 2017.

- Blood tests
 - CBC with diff
 - CMP
 - TSH and free T4
 - HbA1c
 - Total CK
 - Fasting lipid profile
 - Infectious disease screen:
 - Hepatitis serologies
 - CMV antibody
 - HIV antibody and antigen (p24)
 - TB testing (T-spot, quantiferon gold)





Approach to Treatment

- Treatment approach is guided by grading of specific toxicity
- Resources for grading:
 - SITC Toxicity Management Working Group
 - Common Terminology Criteria for Adverse Events
 - National Comprehensive Cancer Network
- 1st line for **MOST** irAEs is systemic high-dose corticosteroids
 - Endocrine toxicities managed with hormone replacement
 - Some grade 1-2 irAEs may respond to topical steroids (dermatologic, ophthalmologic)
- OTC drugs may not be appropriate for managing symptoms
 - i.e. loperamide for colitis may result in bowel perforation and mask underlying symptoms





General corticosteroid management

Grade of irAE	Corticosteroid Management	Additional Notes
1	Usually not indicated	Continue immunotherapy
2	 Start prednisone 0.5-1 mg/kg/day (or equivalent dose of IV methylprednisolone) If no improvement in 2-3 days, increase dose to 2 mg/kg/day Once improved to ≤grade 1, start 4-6 week steroid taper 	 Hold immunotherapy during corticosteroid use Continue immunotherapy once resolved to ≤grade 1 and off corticosteroids Start proton pump inhibitor for GI prophylaxis

© 2020–2021 Society for Immunotherapy of Cancer

Pazanov & Diab, JITC 2017.



General corticosteroid management

Grade of irAE	Corticosteroid Management	Additional Notes
3	 Start prednisone 1-2 mg/kg/day (or equivalent dose of IV methylprednisolone) If no improvement in 2–3 days, ADD additional immunosuppressant Once improved to ≤ grade 1, start 4–6-week steroid taper 	 Hold immunotherapy; if unable to taper steroids over 4-6 weeks, discontinue immunotherapy Start proton pump inhibitor for GI prophylaxis Add PJP prophylaxis if more than 3 weeks of immunosuppression expected (>30 mg prednisone or equivalent/day)
4		 Discontinue immunotherapy Start proton pump inhibitor for GI prophylaxis Add PJP prophylaxis if more than 3 weeks of immunosuppression expected (>30 mg prednisone or equivalent/day)



HOPA

sitc

Society for Immunotherapy of Cance



Additional immunosuppressives for specific toxicities

Colitis

Infliximab anti-TNF-α antibody Dose: 5 mg/kg; 2nd dose may be administered after 2 weeks

Vedolizumab A4β7 inhibition; gut-selective Dose: 300 mg; repeat dose at 2 and 6 weeks

Pneumonitis

Mycophenolate mofetil Inhibits T and B cell proliferation Dose: 1 g twice per day

High dose intravenous immunoglobulin (hdIVIG)

Cutaneous

Topical tacrolimus Calcineurin inhibitor

Indication-specific treatments Pemphigus or bullous phemphigoid: rituximab Eczema: dupilumab Lichenoid rash: infliximab Urticaria: omalizumab







- Incidence, onset and severity grading
- Immune checkpoint inhibitors
 - Common adverse events
 - Rare but serious adverse events
 - Impact of irAEs on cancer outcomes
- Cellular therapies
 - Adverse events and management
- Immunotherapy in special patient populations
- Case studies





Uncommon irAEs with ICIs

Endocrine: Cardiovascular: Renal: Adrenal insufficiency, Interstitial nephritis, Myocarditis, pericarditis, pancreatic insufficiency, arrhythmias granulomatous nephritis type 1 diabetes mellitus Hematologic: Neurologic: **Ophthalmologic:** Hemolytic anemia, red Myasthenia gravis, Uveitis, episcleritis, Guillain-Barré syndrome, cell aplasia, neutropenia, conjunctivitis thrombocytopenia

Puzanov and Diab, JITC 2017. NCCN Guidelines. Management of immunotherapyrelated toxicities. Version 2.2019.

© 2020–2021 Society for Immunotherapy of Cancer

peripheral neuropathies



#LearnACI



Uncommon irAEs with ICIs

Cardiovascular:

Myocarditis, pericarditis, arrhythmias

Renal:

Interstitial nephritis, granulomatous nephritis

Endocrine:

Adrenal insufficiency, pancreatitis, type 1 diabetes mellitus

Hematologic:

Hemolytic anemia, red cell aplasia, neutropenia, thrombocytopenia

Puzanov and Diab, JITC 2017. NCCN Guidelines. Management of immunotherapyrelated toxicities. Version 2.2019.

© 2020–2021 Society for Immunotherapy of Cancer

Neurologic:

Myasthenia gravis, Guillain-Barré syndrome, peripheral neuropathies

Ophthalmologic:

Uveitis, episcleritis, conjunctivitis





#LearnACI



Fatal Events with ICIs

Cases and fatality rates








Wang et al, JAMA Oncol 2018.



Myocarditis

- More common with anti-CTLA-4 than anti-PD-1, but highest with combination
- Symptoms: dyspnea, chest pain, fatigue, myalgia, palpitations, syncope, dizziness
- Imaging findings usually normal
- Increased serum troponin in almost all patients
 high suspicion of ICI-associated myocarditis!
- Management includes:
 - Withholding immunotherapy
 - Immunosuppressives based on grade of myocarditis
 - Heart failure support
- Often overlaps with other irAEs





Type 1 diabetes

• Diagnostic workup

- Most common with PD-1 pathway inhibitors
- Symptoms: severe and sudden onset of hyperglycemia, diabetic ketoacidosis
- Monitor glucose levels at each dose of immunotherapy
- Management
 - Typically do not respond to immunosuppressives
 - Requires insulin therapy










- Incidence, onset and severity grading
- Immune checkpoint inhibitors
 - Common adverse events
 - Rare but serious adverse events
 - Impact of irAEs on cancer outcomes
- Cellular therapies
 - Adverse events and management
- Immunotherapy in special patient populations
- Case studies






No significant difference in survival in melanoma patients who discontinued ipilimumab + nivolumab due to irAEs versus those who did not discontinue treatment

sitc

Autoimmunity as a prognostic marker?



Based on **retrospective** data, patients who experience irAEs (regardless of needing treatment) may have better outcomes compared to patients who do not experience irAEs

Abu-Sbeih, J Immunoth Prec Oncol 2018.

(sitc)


ADVANCES IN


Society for Immunotherapy of Cancer





Impact of steroid management on patient outcomes





De Giglio, Mezquita et al, ESMO-IO 2020.




sitc



Rechallenging with ICIs after irAEs

- Patients should not be rechallenged until irAE resolved to grade ≤1
- Re-challenge with anti-PD-1/L1 after anti-CTLA-4 <u>+</u> anti-PD-1 likely safe
- Caution in re-challenging with same ICI in patients who previously had grade 3-4 irAEs








- Incidence, onset and severity grading
- Immune checkpoint inhibitors
 - Common adverse events
 - Rare but serious adverse events
 - Impact of irAEs on cancer outcomes
- Cellular therapies
 - Adverse events and management
- Immunotherapy in special patient populations
- Case studies





#LearnAC

© 2020–2021 Society for Immunotherapy of Cancer

related toxicities. Version 2.2019.








CRS and Neurotoxicity

- Should not be viewed as two unrelated adverse events
 - Overlapping toxicities from excessive immune activation
 - May occur together or exclusive of one another
 - However, they do have distinct timing and responses to treatment
- Risk factors for both include:
 - High disease burden
 - Higher infused CAR-T cell dose
 - High intensity lymphodepletion regimen
 - Pre-existing endothelial activation
 - Severe thrombocytopenia





Cytokine release syndrome



Riegler LL. Ther Clin Risk Manag 2019.

© 2020–2021 Society for Immunotherapy of Cancer

#LearnACI





- Inflammatory syndrome caused by hyperactivation of macrophages and lymphocytes
- Rare; frequency reported to be as low as ~1%
- Should be managed with anti-IL-6 and corticosteroid therapy
- If no improvement after 48 hours, consider adding etoposide for additional immunosuppression
 - Dose: 75-100 mg/m²
 - May be repeated after 4-7 days

Box 5 | Diagnostic criteria for CAR-T-cell-related HLH/MAS

A patient might have HLH/MAS if he/she had a peak serum ferritin level of >10,000 ng/ ml during the cytokine-release syndrome phase of CAR-T-cell therapy (typically the first 5 days after cell infusion) and subsequently developed any two of the following:

- Grade ≥3 increase in serum bilirubin, aspartate aminotransferase, or alanine aminotransferase levels*
- Grade \geq 3 oliguria or increase in serum creatinine levels*
- Grade ≥3 pulmonary oedema*
- Presence of haemophagocytosis in bone marrow or organs based on histopathological assessment of cell morphology and/or CD68 immunohistochemistry







- Incidence, onset and severity grading
- Immune checkpoint inhibitors
 - Common adverse events
 - Rare but serious adverse events
 - Impact of irAEs on cancer outcomes
- Cellular therapies
 - Adverse events and management
- Immunotherapy in special patient populations
- Case studies





Patients with autoimmune disorders

- Ipilimumab in melanoma patients
 - 29% experienced flare of pre-existing disorder; 29% experienced new irAEs
 - 56% experienced no flare OR additional irAEs
- PD-1 in melanoma patients
 - 38% experienced flare; 29% experienced new irAEs
 - Lower response rates in patients who remained on immunosuppressive treatment (15% vs 44%)
- Efficacy appears similar for patients with autoimmune disorders compared to those without







ICI use in patients with solid organ or stem cell transplants

- Patients who relapse after allogeneic SCT:
 - Ipilimumab: 32% response (10 mg/kg); 14% GVHD; 21% irAEs
 - Anti-PD-1: 77% response; 26% died due to new-onset GVHD
- Solid organ data is limited; most is in renal SOT patients
 - One retrospective study (n=39) reported graft loss in 81% and death in 46%
 - Also reported rapid time to rejection with median onset of 21 days
- PD-1 pathway appears to be more critical in allograft immune tolerance compared to CTLA-4 pathway





The importance of patient education

- Many immune-related adverse events can present in similar ways to other diseases, but the treatment of them is very different.
- Patients need to be able to identify themselves as immunotherapy recipients
- Reassure patients that irAEs will likely resolve over time (except endocrinopathies)






Education along the healthcare continuum

- Patients may not go back to their original clinic for adverse event management
- Emergency departments and primary care physicians need to recognize and know how to manage irAEs
- For example, the most common irAE in emergency departments is diarrhea – recognize immune-related symptoms versus other causes (including chemotherapy related diarrhea)





Additional Resources




SPRINGER PUBLISHING

ACCESS

MARC S. ERNSTOFF IGOR PUZANOV CAROLINE ROBERT ADI DIAB PETER HERSEY

(sitc)









#LearnACI





- 60 yom with metastatic melanoma to the liver was receiving nivolumab called clinic feeling unwell. He reported muscle cramping, cotton mouth, significant fatigue, 17 pound weight loss in 2 weeks, significant thirst. On examination, his vital signs are normal except for HR of 110 bpm, he appears fatigued but arrives ambulatory, mucus membranes dry with no other abnormalities.
- What would you include on your initial evaluation?
 - A. CBC/DIFF, CMP
 - B. TSH
 - C. CK
 - D. Cortisol
 - E. All of the Above





Case Study 1

- BG 468 \rightarrow 628
- Na 124, HCO3 16, Cr 0.9, ALT 59, AST 44
- TSH 8.79, FT4 1.0
- Cortisol NI
- CK NI
- UA: 3+ Glucose, Large ketone







- Hospitalized for IV fluid and IV Insulin
- Endocrinology consult: ICPI-Induced Diabetes mellitus
- Discharged on Insulin
- Resumed Nivolumab and no other irAE develops





Patient Case 2

- 65 yom with advanced melanoma s/p 1 dose pembrolizumab called with new onset hemoptysis 3 weeks after treatment.
- What would you do?
 - A. Send to the ER
 - B. Bring to clinic for same day assessment
 - C. Order CXR
 - D. Order CT Chest












Patient Case 2

- Patient admitted. O2 requirements increased rapidly over the first several days of admission.
- What additional diagnostics/consults would you call?
 - A. Pulmonary Consult
 - B. Infectious Disease Consult
 - C. Perform organ biopsy
 - D. Echocardiogram
- Worsening hypoxia, required intubation











© 2020–2021 Society for Immunotherapy of Cancer






- Steroids added
- Bronchoscopy next AM: "entire tree erythematous but there was no active bleeding. In fact, mucosa was not friable with suctioning"
- Next day: extubated
- 4 days later, discharged home without O2.





Patient Case 2





sitc

HOPA



Acknowledgements

• Some figures created using Biorender.com

